LOS ANGELES--(BUSINESS WIRE)--Cancer Therapeutics Laboratories (CTL), a California-based biopharmaceutical company committed to the research, development and commercialization of cancer treating therapies, today announced that it has filed a cross-complaint against Tustin, Calif.-based Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), in a licensing rights dispute over an antibody technology called Tumor Necrosis Therapy (TNT), a method used for locating and killing cancer cells.
